Fig 1: Selective IDO1 gene deletion in cDC1 worsens EAE(A) EAE score in WT and Irf8 Δ32−/− mice. Five mice per group, n = 3.(B) IL-17, GM-CFS, and TGF-β in supernatant of cervical LNs from EAE mice in (A) at day 28 and restimulated in vitro with MOG 20 μg/mL for 5 days.(C) H&E staining of spinal cord sections from EAE mice in (A).(D) Flow cytometric analysis of FoxP3+CD25+ cells in cervical LNs of mice immunized as in (A).(E) Schematic representation of Ido1f/fXcr1Cre/+ strain generation.(F) IDO1 immunoblot. Left: cDC1 untreated or treated with LPS 250 ng/mL for 48 h. Right: macrophages (MΦ) untreated or treated with LPS 250 ng/mL and IFN-γ 15 ng/mL for 48 h β-actin was used as loading control (n = 3).(G) Flow cytometric analysis of PDL1+ in thymic cDC1.(H) EAE score in Ido1f/f Xcr1+/+ and Ido1f/fXcr1cre/+ mice. 9 mice per group, n = 2.(I) H&E staining of spinal cord sections from mice treated in (H).(J) Quantification of cDC1 and cDC2 in spinal cords from EAE mice in (H) at day 26.(K) PDL1+ cDC1 frequency out cDC1 by flow cytometry in spinal cords of EAE mice in (H).(L) Cytokine analysis in supernatants from cervical LNs of EAE mice in (H) at day 26 stimulated as in (B).(M) Flow cytometric analysis of FoxP3+CD25+ cells in cervical LNs of mice immunized as in (H).(N) Tryptophan metabolites in plasma from EAE mice in (H) at day 26.(O) Il6 mRNA expression in cervical LNs from EAE mice in (H).(P) EAE score in Irf8 Δ32−/− mice transferred with cDC1 genotypes at days 4 and 7 post immunization. 5 mice per group, n = 3.Data are mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, two-way ANOVA followed by Bonferroni multiple comparison test (A, H, and P) or unpaired t test (B, D, G, and J–O). Each dot represents an individual value. Please also see Figure S3.